Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.: sirolimus and m-TOR pathway polymorphisms

Abstract : BACKGROUND: The mammalian target of rapamycin (m-TOR) inhibitor sirolimus is an immunosuppressive drug used in kidney transplantation. m-TOR binds with Raptor and phosphorylates p70S6 kinase, a protein involved in numerous cell signalling pathways. We examined the association of candidate polymorphisms in m-TOR, Raptor and p70S6K, sirolimus dose and exposure, and other time-independent as well as time-dependent covariates, with sirolimus-induced adverse events in kidney transplant recipients. METHODS: This study included a first group of 113 patients, switched from a calcineurin inhibitor to sirolimus, and a validation group of 66 patients from another clinical trial, with the same immunosuppressive regimen. The effects of gene polymorphisms and covariates on the total cholesterol, LDL cholesterol, triglycerides, haemoglobin, cutaneous adverse events, oedemas and infections were studied using multilinear regression, or logistic regression imbedded in linear mixed-effect models. RESULTS: An m-TOR variant haplotype was significantly associated with a decrease in haemoglobin levels in the two populations of patients (discovery group: β=-0.82 g/dl, P=0.0076; validation group: β=-1.58 g/dl, P=0.0308). Increased sirolimus trough levels were significantly associated with increased total cholesterol levels (discovery group: β=0.02 g/l, P<0.0001; validation group: β=0.02 g/l, P=0.0002) and triglyceride levels (discovery group: β=0.02 g/l, P=0.0059; validation group: β=0.05 g/l, P=0.0370). Sirolimus trough levels were also associated with an increased risk for cutaneous adverse events [odds ratio=1.97, 95% confidence interval (1.32-1.94), P=0.0009] and oedemas [odds ratio=1.16, 95% confidence interval (1.03-1.30), P=0.01342] in the discovery group, but this was not confirmed in the validation group. CONCLUSION: These results provide evidence of an association between an m-TOR haplotype and a decrease in haemoglobin in renal transplant recipients.
Type de document :
Article dans une revue
Pharmacogenet Genomics, 2012, 22 (10), pp.725-32. 〈10.1097/FPC.0b013e328357359d〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00724758
Contributeur : Pierre Marquet <>
Soumis le : jeudi 22 août 2013 - 07:00:04
Dernière modification le : mardi 11 septembre 2018 - 15:18:46
Document(s) archivé(s) le : samedi 23 novembre 2013 - 02:25:14

Fichiers

Woillard_et_al_PGgenomics_Revi...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Jean-Baptiste Woillard, Nassim Kamar, Annick Rousseau, Lionel Rostaing, Pierre Marquet, et al.. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.: sirolimus and m-TOR pathway polymorphisms. Pharmacogenet Genomics, 2012, 22 (10), pp.725-32. 〈10.1097/FPC.0b013e328357359d〉. 〈inserm-00724758〉

Partager

Métriques

Consultations de la notice

382

Téléchargements de fichiers

495